Briefs - Page 3 of 3 - Center for Medical Economics and Innovation

Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases

June 12, 2019 Briefs, Issues, Resources, Studies

The World Health Organization (WHO) is advocating that the price of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical Economics and Innovation at the non-partisan Pacific Research Institute. “Cancer medications have revolutionized treatment, and it is unfortunate if the WHO’s flawed analysis jeopardizes patients’ access to these life-saving medicines” says...

PRI Launches New Center for Medical Economics and Innovation

April 23, 2019 Briefs

SAN FRANCISCO – California-based nonpartisan think tank the Pacific Research Institute today announced the launch of a new Center for Medical Economics and Innovation, which will research and advance policies showing how a thriving biomedical and pharmaceutical sector benefits both patients and economic growth. Timely research, analysis and commentary relating to medical innovation will be available at the new Center’s website - www.medecon.org. “Medical innovation is important to alleviating deadly diseases and helping Americans live long and healthy lives, and it’s also...

Nevada proposal to regulate excess costs are price controls by another name

April 24, 2017 Briefs, Price and Costs

De facto price controls will impose heavy costs on Nevada that include higher health care costs and lower health care quality....

Oregon Proposal To Regulate Excess Costs Is Price Controls By Another Name

March 1, 2017 Briefs, Price and Costs

The bill is a creative way to impose price controls, which will impose heavy costs on Oregon, that include higher health care costs, and lower health care quality....

Improving the Incentive to Innovate

June 22, 2016 Briefs, Innovation

Innovations in the pharmaceutical industry have significantly improved health outcomes for patients and have made important contributions to the U.S. economy. Provisions in the 21st Century Cures bill would help address these problems by accelerating the approval process for innovative pharmaceutical drugs and as a result, extend the effective patent lives for new pharmaceutical innovations....